Compare Garmin Ltd. (GRMN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Garmin Ltd. trades at $281.37 (market cap $53.31B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Garmin Ltd. is far larger — about 7.1× Spyre Therapeutics Inc. Common Stock's market cap, and Garmin Ltd. pays a 1.52% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 84 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GRMN | SYRE | |
|---|---|---|
Market Cap | $53.31B | $7.52B |
Volume | 778,898 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $313.16 | $108.92 |
52-Week Low | $187.10 | $22.18 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $50.82B | $6.52B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $279.72, up 4.86% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bearish technical signals but maintains robust fundamentals with 24.47% net margins and consistent revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent positive news includes product awards and institutional accumulation, though technical indicators suggest near-term resistance.
GRMN presents a mixed outlook: strong profitability and analyst consensus target of $320.25 offer 14.5% upside, but bearish technicals and high valuation ratios (P/E 28.53) pose risks. Investment appeal hinges on execution of 2026 revenue guidance ($7.7B) amid competitive pressures in consumer electronics.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
